Gary Beale, chief executive, Emblation By Scott Wright AN Alloa-based medical device company that makes microwave-based solutions for skin conditions has secured an “eight-figure” investment to underpin its international growth ambitions. Emblation, which has developed a non-ablative treatment for common and plantar warts, has received the backing from Apposite Capital, a healthcare investor. It said the investment would “accelerate” its global growth plans as it targets doubling its current headcount of 25. Two new directors, Rory Pope of Apposite Capital and Jim Atkinson, who held a senior role at former Apposite portfolio company Ulthera Inc, have joined the board. Emblation’s systems are currently sold in the UK, North America, and Australia, and have been used in more than 130,000 treatments to date.